Fig. 1

Treatment efficiency of different anti-HER2 antibodies in vitro. a SK-BR-3, MDA-MB-361, and MDA-MB-453 were treated with a total concentration of 2 µg/ml for 72 h and S-phase fraction (SPF, a) or apoptosis b in comparison to untreated control cells is displayed. Untreated controls were set 100% and differences from the control are shown for each antibody treatment. Significant differences are only indicated in relation to control and trastuzumab (a, b) or B100 (b) treatment. Tukey’s multiple comparisons test was applied and significances are indicated (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Trast, trastuzumab; Pert, pertuzumab